Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Creative Commons License

Teerlink J. R., Diaz R., Felker G. M., McMurray J. J. V., Metra M., Solomon S. D., ...More

EUROPEAN JOURNAL OF HEART FAILURE, vol.22, no.11, pp.2160-2171, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 11
  • Publication Date: 2020
  • Doi Number: 10.1002/ejhf.2015
  • Journal Name: EUROPEAN JOURNAL OF HEART FAILURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.2160-2171
  • Keywords: Heart failure, Omecamtiv mecarbil, Cardiac myosin activator, Inotrope, Myotrope, Cardiovascular outcomes trial, CARDIAC MYOSIN ACTIVATOR, INCREASE CONTRACTILITY, TOLVAPTAN, MORTALITY, OUTCOMES, PHASE-2, WOMEN
  • Dokuz Eylül University Affiliated: Yes

Abstract

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.